Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Novo Nordisk ( NVO 1.82%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.